ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

How Good Fats Prevent Heart Disease

The Bees' Best-Kept Secret: The Amazing Health Benefits of Propolis

Acupuncture: Why It Works

The Relationship Between Vitamin D and Insulin Resistance

For women, healthy diets may help with mobility when aging

High-Quality Whey Protein (in the Right Amounts) May Be Helpful for Weight Loss

8 Things to Consider for Depression

VIDEO: Living with Chronic Pain

Turmeric: The Spice of Life

Bone Broth Benefits for Digestion, Arthritis and Cellulite

 
Print Page
Email Article

Genetically Engineered Cold Virus Appears to Kill Cancer

  [ 112 votes ]   [ Discuss This Article ]
www.ProHealth.com • April 29, 2002




New research is using a genetically engineered version of a common cold virus to treat colon and other gastrointestinal cancers that have spread to the liver. In a report presented at the 27th Annual Scientific Meeting of the Society of Cardiovascular & Interventional Radiology (SCVIR), investigators in a multi-center study report that a therapeutic adenovirus, when injected into the artery leading to the liver, appears to kill tumors without harming healthy liver tissue.

"You could think of this virus as a new generation of chemotherapy that is much more selective about what it attacks," said Daniel Y. Sze, M.D., Ph.D., assistant professor of radiology at Stanford University Medical Center, Stanford, Calif. "Standard chemotherapy kills some healthy cells along with the cancer. This engineered adenovirus is designed to kill only the cancer and not to harm healthy cells."

The therapy is genetically based, but is not gene therapy in the strictest sense.

"Normally with gene therapy, a specific gene is spliced into a deactivated virus, and the virus acts as a 'vector,' a vehicle to get the gene inside the body's cells," said Dr. Sze. "In this case, we're using the live virus itself -- without any extra gene -- as the treatment. Rather than inject it directly into the tumor using a syringe and needle, where it might not get distributed evenly, we inject it into the artery, so that the flow of blood carries it throughout the liver, treating the entirety of each tumor."

People with cancer that has spread to the liver typically have multiple tumors in the liver.

The synthetic virus is alive, but is genetically engineered to be weaker, and therefore it is not as highly infectious as a normal cold virus. According to Dr. Sze, it was designed to infect only cells with an abnormality in the tumor suppressor gene, p53, which may be why those cells are susceptible to cancer to begin with. P53 is part of the body's own surveillance system, which detects and destroys most early cancers. About one-half to two-thirds of cancers have abnormal p53 function.

Most patients feel sick with a mild flu for up to a week after the injection, although not as ill as they typically feel after standard chemotherapy, said Dr. Sze. Unlike most viruses used in gene therapy, this virus retains the ability to replicate, and, because it copies itself, the virus is very effective at depleting the cancerous cell's resources and killing it. When the cancerous cell dies, it breaks open and releases the virus and all its copies, which can then infect other cancerous cells and start the process again.

"The serendipitous finding was that although the lack of p53 makes a cell mean, aggressive and cancerous, it also can not recognize when it's been infected by a virus," said Dr. Sze. "That is its Achilles' heel: it makes the cell particularly susceptible to viral infection by this particular engineered virus."

The multi-center trial was conducted at Stanford, the Mayo Clinic, Rochester, Minn.; and M.D. Anderson Cancer Center, Houston. It was a dose-escalation Phase I trial, meaning its purpose was to determine whether the treatment is safe and what dose can be tolerated by patients. The trial included a Phase II extension, in which some patients were treated with a high dose.

All 35 patients had gastrointestinal cancer -- most originating in the colon -- that had spread to the liver. Each had a life expectancy of approximately six months without this treatment. None were candidates for surgical removal of the liver tumor or tumors. Almost all had received chemotherapy, which was either unsuccessful or worked only temporarily.

After receiving the genetically engineered virus, none of the patients experienced toxic symptoms to the point where therapy needed to be stopped, even at the highest dose level. Dr. Sze said the results indicate the therapy is safe and research can progress to further Phase II efficacy studies.

Although a Phase I trial is designed to test for safety only, in this completed trial researchers found early evidence that the therapy does suppress tumors when it is administered in higher doses. The median survival time of the 28 patients who received the highest doses given in the trial was 369 days, about 1 year. The average expected survival time was approximately 180 days, or about 6 months. The suggestion of a beneficial effect will need to be proven in subsequent trials.

Computed tomography (CT) imaging showed that the tumors appeared to grow slightly larger immediately after the treatment, which was suspected to be an inflammatory response to the viral infection. The tumors then slowly got smaller.

"The tumors shrank somewhat, but more impressive was that blood tests showed that abnormal proteins being secreted by the tumors either decreased significantly, or became completely undetectable," said Dr. Sze. "That suggests the tumors, although still visible on the CT scan, are dying or dead."

In the Phase II study, due to start this year at the same institutions, investigators will treat cancer patients with the virus as well as chemotherapy to try to confirm the beneficial effects of the virus.

"This virus seems to have an additive affect with chemotherapy," said Dr. Sze. "It could be years before this treatment is ready for prime time, but it could eventually be a frontline therapy to treat various types of primary cancer, as well as tumors that have spread from the original site."



Post a Comment

Featured Products From the ProHealth Store
Mitochondria Ignite™ with NT Factor® FibroSleep™ Vitamin D3 Extreme™

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
Natural Pain Relief Supplements

Featured Products

Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid

Natural Remedies

When a Good Night's Sleep Is Just a Daydream... When a Good Night's Sleep Is Just a Daydream...
Ubiquinol - A More Advanced Form of the Energy Producing Nutrient CoQ-10 Ubiquinol - A More Advanced Form of the Energy Producing Nutrient CoQ-10
Clinically Studied Joint Relief Product for FM & ME/CFS Clinically Studied Joint Relief Product for FM & ME/CFS
SAM-e: a Hard-Working Molecule that May Help Ease Pain & Brighten Mood SAM-e: a Hard-Working Molecule that May Help Ease Pain & Brighten Mood
Cocoa's Polyphenol Riches - All the Health Benefits without the Sugar, Calories or Guilt Cocoa's Polyphenol Riches - All the Health Benefits without the Sugar, Calories or Guilt

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE AND SAVE 15% NOW*
Be the first to know about new products, special discounts and the latest health news. *New subscribers only

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map